| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06bc0c2d1b16f9d16470b7e30874649 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B53-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B53-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-32 |
| filingDate |
2016-09-02^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b72b90ddf24b914175f8d62ab57a667d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b5569130b6b2127e660d8b876a1356f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23a45cd806055b2017495dcd768976db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aaff7796a4461c38afa0539c3ff2e14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21d807c6463a62c8c911869298e00ed7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_532f7fa7a8877360fbbd67eba7285d5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b64fe375196c84637db8b7c83182f77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_193031627ce5cadcd7a08e4bdc842648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3e25e5c32faab476122d6f5773b48a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ccc0caec480ad773819211057d8e8f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b174762122093a3fa06cf6e7594be2b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fce06734e72206c7580400ab4a9dd7ca |
| publicationDate |
2017-03-09^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017037662-A1 |
| titleOfInvention |
An improved process for the preparation of paroxetine and its intermediate |
| abstract |
The present invention provides an improved process for the preparation of N-protected ((3S,4R)- 4-(4-fluorophenyl)piperidin-3-yl)methanol (compound (A)) and further its transformation to Paroxetine and its pharmaceutically acceptable salts. The process comprises reaction of compound (II) with amido-malonate compound (C) in the presence of a chiral catalyst and optionally a dehydrating agent to obtain compound (B); followed by reduction of (B) in the presence of a reducing agent to provide compound (A). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022269643-A1 |
| priorityDate |
2015-09-03^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |